$CL

Wallace Noel R. sold $29.7M of CL

Wallace Noel R. (Chairman, President & CEO) sold 322,042 shares of COLGATE PALMOLIVE CO (CL) at an average of $92.22 ($91.92–$92.52, $29.70M total) across 2 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · Wallace Noel R.
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CL
Neutral
medium confidence
Mentioned
$CL
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence short-term sentiment, but it does not provide new information about earnings, guidance, or business performance.

02

Market read

Traders may monitor CL for sentiment effects from insider selling, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

No 10b5-1 plan details are provided in the text, and insider sales often have non-informational motives; traders should avoid over-weighting without corroborating fundamentals or guidance changes.

Relevance 7/10Novelty 5/10Timing: Form 4 filed 2026-08-06, covering sales on 2026-08-04 to 2026-08-05.

Background

The article is a SEC Form 4 insider transaction disclosure for Colgate-Palmolive (CL) by its Chairman, President and CEO.

Company-level read

Ticker impact

$CLNeutralMedium confidence
Context

Colgate-Palmolive CEO Wallace Noel R. sold 322,042 shares in open-market transactions totaling about $29.7M, per Form 4 filed Aug. 6.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan disclosed and no accompanying operational or guidance change in the text.

Market effects

Minimal. Large-cap consumer staples insider sales are typically not sector-moving without additional company-specific catalysts.

None indicated.

None indicated.

Counterpoint

The sale could be planned liquidity management rather than a bearish signal, especially given the multi-day execution window.

Key entities

  • Colgate-Palmolive Co

    Subject of the Form 4 insider sale disclosure.

  • Wallace Noel R.

    Chairman, President and CEO who sold 322,042 shares for about $29.7M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGMed

Weather Dividend Stocks That Keep Writing Bigger Checks

Procter & Gamble (PG) raised its dividend for 70 consecutive years, with fiscal 2026 free cash flow of $15.835B. Coca-Cola (KO) reported 5% unit case volume growth, its strongest in 17 years. Colgate-Palmolive (CL) saw 16.12% YTD stock growth and raised its dividend. All three companies demonstrated recession-resilient cash flows and dividend increases.

$PGMedAI 8/10

2 Dividend Kings, 1 Clear Winner: P&G vs. Colgate

Procter & Gamble (PG) and Colgate-Palmolive (CL) recently paid dividends. PG offers a higher yield (2.93%) and better coverage, while CL has stronger recent price performance. PG plans to return $15B to shareholders in fiscal 2027, including $10B in dividends. CL trades at a higher P/E (35x) with a smaller yield (2.33%).

$CLHigh

Colgate-Palmolive India Share Price Target at Rs 2,500: Motilal Oswal

Motilal Oswal reaffirmed a BUY rating for Colgate-Palmolive India, setting a price target of Rs 2,500, a 27% upside from the current price of Rs 1,965. The brokerage values the company at 40 times its estimated March 2027 earnings, citing strong growth pillars, premiumisation, and high margins. Colgate's strategy focuses on consumption creation and scientific premiumisation, with a 52-week range of Rs 1,782–2,505.